Beta cell function in insulin-treated non-insulin-dependent diabetic patients

Area of Science:

• Endocrinology
• Metabolic Disorders
• Diabetes Mellitus Research

Background:

• Non-insulin-dependent diabetes mellitus (NIDDM) management often involves insulin therapy, raising questions about its long-term effects on beta cell function.
• The role of anti-insulin antibodies in modulating beta cell response in NIDDM patients requires further investigation.

Purpose of the Study:

• To investigate the impact of long-term insulin therapy on beta cell function in NIDDM patients.
• To assess the influence of anti-insulin antibodies on beta cell function in this cohort.
• To evaluate the potential for switching NIDDM patients from insulin to oral hypoglycaemic agents (OHA).

Main Methods:

• Studied 94 NIDDM patients on insulin therapy for 2-10 years.
• Measured insulin antibody titers and stimulated C-peptide (CP) levels.
• Assessed patient response to switching to OHA versus continued insulin therapy.

Main Results:

• No correlation found between insulin antibody titers, insulin dose, therapy duration, or hyperglycemia severity.
• Antibody titers were low, moderate, or high in 45%, 10%, and 45% of patients, respectively, with no link to CP values.
• 54 patients achieved good glycemic control after switching to OHA, showing improved CP values; 40 continued insulin therapy.

Conclusions:

• Beta cell response to exogenous insulin is heterogeneous in NIDDM patients.
• Many NIDDM patients maintain adequate beta cell function after prolonged insulin use and can benefit from OHA.
• Insulin antibodies do not appear to affect the secretory status of beta cells in NIDDM patients.